Lisa is an accomplished corporate development executive providing strategic and business advice to biotech companies. She has experience in a broad range of therapeutic areas and has supported drug discovery and platform companies advancing small molecules, biologics and gene therapies. Lisa has a proven track record of developing and executing corporate strategy as well as evaluating, structuring and negotiating R&D collaborations, acquisitions and licensing agreements. She is skilled in preparing pitch material for venture capital fundraising and for pharmaceutical and biotech partnerships. She has worked with many start-ups to build strong relationships with patient advocacy groups, rare disease foundations, KOLs, and academic collaborators. As a leadership team member, Lisa has been responsible for establishing and growing functions such as alliance management and corporate communications.
Trained as a biochemist, Lisa has over 25 years of experience in the biotech industry starting in drug discovery research as a post-doc at Genentech and later transitioning into business development roles. As Senior Vice President of Corporate Development and Strategic Relations at Mitobridge, Lisa helped launch the company and negotiate the “build to buy” option deal with Astellas Pharma. Astellas acquired Mitobridge in January 2018. Lisa was Senior Director at Ensemble Discovery and worked in the business development group at Biogen Idec where she played a central role in M&A, licensing and R&D collaborations. She completed numerous deals including the oncology partnership that ultimately led to the merger between Biogen and Idec. Lisa spent several years at Gilead Sciences, initially as a group leader in discovery research and then in business development.
Lisa earned a BS in biochemistry from SUNY Binghamton, a PhD in cancer biology from Stanford University.